Product Description
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Italfarmaco
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Spain, United Kingdom, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Muscular Dystrophy, Duchenne|Polycythemia Vera
Phase 2: Oncology Unspecified
Phase 1: Healthy Volunteers|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DSC/11/2357/44 | P2 |
Unknown Status |
Oncology Unspecified |
2029-09-30 |
|
| DSC/14/2357/52 | P2 |
Unknown Status |
Muscular Dystrophy, Duchenne |
2028-12-31 |
|
| ULYSSES | P3 |
Recruiting |
Muscular Dystrophy, Duchenne |
2028-02-01 |
|
| DSC/14/2357/50 | P3 |
Unknown Status |
Muscular Dystrophy, Duchenne |
2027-12-30 |